Fitoterapia · 2025
Protective effects of Polygonum cuspidatum bioactive constituents against cholestatic liver injury: A mechanistic review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Zengni, Yang Xiao, Fu Yan, Wei Huilin, Chen Yajuan, Dai Anlin, Zhou Xia, Wan Jun, Chen Wenwen
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Polygonum cuspidatum Sieb. et Zucc. has long been prescribed in Traditional Chinese Medicine for jaundice, hepatitis, and cholestasis. Its major stilbenes (polydatin, resveratrol) and anthraquinones (emodin, quercetin) exhibit clinically relevant hepatoprotective effects.
AIM OF THE REVIEW: To systematically summarize mechanistic evidence for P. cuspidatum and its bioactive constituents in experimental models of cholestatic liver injury (CLI) and to evaluate their translational potential.
MATERIALS AND METHODS: Literature was retrieved from PubMed, Web of Science, Scopus, and CNKI through June 2025. Data on pharmacodynamics, signaling pathways, and efficacy endpoints were extracted and synthesized.
RESULTS: Polydatin, resveratrol, emodin, and quercetin alleviate CLI by regulating bile-acid synthesis and transport via the farnesoid X receptor (FXR), pregnane X receptor (PXR), and bile salt export pump (BSEP); activating Nrf2-dependent antioxidant defenses; suppressing NF-κB-mediated inflammation; and inhibiting TGF-β-driven fibrogenesis. Multi-target effects were confirmed in α-naphthylisothiocyanate(ANIT), bile-duct-ligation, and genetic cholestasis models with dose-dependent biochemical and histological improvements.
CONCLUSIONS: P. cuspidatum offers a multi-pathway therapeutic strategy for CLI. Rigorous clinical trials are warranted to define optimal dosing, safety profile, and efficacy in patients.
AIM OF THE REVIEW: To systematically summarize mechanistic evidence for P. cuspidatum and its bioactive constituents in experimental models of cholestatic liver injury (CLI) and to evaluate their translational potential.
MATERIALS AND METHODS: Literature was retrieved from PubMed, Web of Science, Scopus, and CNKI through June 2025. Data on pharmacodynamics, signaling pathways, and efficacy endpoints were extracted and synthesized.
RESULTS: Polydatin, resveratrol, emodin, and quercetin alleviate CLI by regulating bile-acid synthesis and transport via the farnesoid X receptor (FXR), pregnane X receptor (PXR), and bile salt export pump (BSEP); activating Nrf2-dependent antioxidant defenses; suppressing NF-κB-mediated inflammation; and inhibiting TGF-β-driven fibrogenesis. Multi-target effects were confirmed in α-naphthylisothiocyanate(ANIT), bile-duct-ligation, and genetic cholestasis models with dose-dependent biochemical and histological improvements.
CONCLUSIONS: P. cuspidatum offers a multi-pathway therapeutic strategy for CLI. Rigorous clinical trials are warranted to define optimal dosing, safety profile, and efficacy in patients.